Most Recent Additions*
Recent Developments at the Intersection of Pharma, Patents, and Antitrust Law
Christopher M. Holman
Federal Circuit Reiterates That Drug Safety and Efficacy Are Issues for the FDA, Not the Patent Laws
Christopher M. Holman
GlaxoSmithKline II and Other Recent Developments in Induced and Contributory Patent Infringement
Christopher M. Holman
Recent Developments in the Listing of Patents in FDA's Orange Book
Christopher M. Holman
Antibody Claims and the Evolution of the Written Description/Enablement Requirement
S Sean Tu and Christopher M. Holman
Antibody Patents: Use of the Written Description and Enablement Requirements at the Patent & Trademark Office
S. Sean Tu and Christopher M. Holman
A Performative Model for Conducting Critical Race Analysis: Josephine Baker, Modern Dance, and Utilizing Narrative to Transform Legal Doctrine
Patrick C. Brayer
Use of Technology in the Legal Field
Tara Keever
Will Artifical Intelligence Replace Estate Planners?
Kacie Mihalovich
Document Automation - Final Presentation
Kacie Mihalovich
On the Admissibility of Expert Testimony in Kansas
Mark D. Hinderks and Steve Leben
Long-Arm Jurisdiction in Kansas
Steve Leben and Mark D. Hinderks
Behavior Of Creditors And Involved Stakeholders In The Corporate Insolvency Resolution Process (CIRP) In India: An Economic Perspective
Hiteshkumar Thakkar, Pranay Agarwal, and Randall K. Johnson
*Updated as of 07/26/24.